AOH1996
Експериментални рек против рака.
AOH1996 je eksperimentalni lek protiv raka koji deluje kao inhibitor malih molekula i od avgusta 2023. je u prvoj faza kliničkog ispitivanja za lečenje tumora.[1][2][3][4]
IUPAC ime | |
---|---|
N-[2-[2-(3-methoxyphenoxy)anilino]-2-oxoethyl]naphthalene-1-carboxamide | |
Identifikatori | |
PubChem | CID 126718388 |
Hemijski podaci | |
Formula | C26H22N2O4 |
Molarna masa | 426,47 g·mol−1 |
| |
|
Reference
uredi- ^ Malkas LH, et al. PCNA Inhibitors. Patent WO 2017/049206
- ^ Wang YC, Kelso AA, Karamafrooz A, Chen YH, Chen WK, Cheng CT, et al. (mart 2023). „Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination”. Cell Reports. 42 (4): 112296.
- ^ Gu L, Li M, Li CM, Haratipour P, Lingeman R, Jossart J, et al. (avgust 2023). „Small molecule targeting of transcription-replication conflict for selective chemotherapy”. Cell Chemical Biology. doi:10.1016/j.chembiol.2023.07.001.
- ^ „AOH1996 for the Treatment of Refractory Solid Tumors”. National Cancer Institute. Arhivirano iz originala 2. 8. 2023. g. Pristupljeno 2. 8. 2023.